Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
PF-07265807
i
Other names:
PF-07265807, PF-5807, ARRY-067
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Pfizer
Drug class:
AXL inhibitor, MERTK inhibitor
Related drugs:
‹
BGB324 (26)
TP-0903 (13)
AVB-500 (4)
MGCD265 (4)
ONO-7475 (3)
AB-329 (2)
BPI-9016M (2)
JRF104 (2)
KC1036 (1)
AX-0085 (0)
CTS2016 (0)
INCB81776 (0)
RXDX-106 (0)
S-49076 (0)
SKI-G-801 (0)
SLC-391 (0)
Q702 (0)
BGB149 (0)
UNC2025 (2)
CT053PTSA (1)
MRX2843 (0)
BGB324 (26)
TP-0903 (13)
AVB-500 (4)
MGCD265 (4)
ONO-7475 (3)
AB-329 (2)
BPI-9016M (2)
JRF104 (2)
KC1036 (1)
AX-0085 (0)
CTS2016 (0)
INCB81776 (0)
RXDX-106 (0)
S-49076 (0)
SKI-G-801 (0)
SLC-391 (0)
Q702 (0)
BGB149 (0)
UNC2025 (2)
CT053PTSA (1)
MRX2843 (0)
›
Associations
News
Trials
Filter by
Latest
1m
Study of PF-07265807 in Participants With Metastatic Solid Tumors. (clinicaltrials.gov)
P1, N=67, Active, not recruiting, Pfizer | Trial completion date: Feb 2024 --> Jun 2024 | Trial primary completion date: Feb 2024 --> Jun 2024
1 month ago
Trial completion date • Trial primary completion date • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Inlyta (axitinib) • sasanlimab (PF-06801591) • PF-07265807
10ms
Study of PF-07265807 in Participants With Metastatic Solid Tumors. (clinicaltrials.gov)
P1, N=61, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting | N=161 --> 61
10 months ago
Enrollment closed • Enrollment change • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Inlyta (axitinib) • sasanlimab (PF-06801591) • PF-07265807
over1year
Study of PF-07265807 in Participants With Metastatic Solid Tumors. (clinicaltrials.gov)
P1, N=161, Recruiting, Pfizer | Trial completion date: Feb 2024 --> Jun 2024 | Trial primary completion date: Feb 2024 --> Jun 2024
over 1 year ago
Trial completion date • Trial primary completion date • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Inlyta (axitinib) • sasanlimab (PF-06801591) • PF-07265807
over2years
Study of PF-07265807 in Participants With Metastatic Solid Tumors. (clinicaltrials.gov)
P1, N=155, Recruiting, Pfizer | N=37 --> 155 | Trial completion date: Nov 2024 --> Dec 2023 | Trial primary completion date: Nov 2024 --> Dec 2023
over 2 years ago
Clinical • Enrollment change • Trial completion date • Trial primary completion date
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Inlyta (axitinib) • sasanlimab (PF-06801591) • PF-07265807
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login